Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH2 | Q6NS38 | 2/20 | 0.58 |
| ▸ | HPGDS | O60760 | 1/20 | 0.58 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.57 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.51 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861126 | 0.77 | ALKBH2 (0.63) | ALKBH2HPGDSALKBH1EGLN1 | |
| SCHEMBL11480162 | 0.77 | ALKBH2 (0.63) | ALKBH2HPGDSALKBH1EGLN1 | |
| SCHEMBL22209199 | 0.77 | ALKBH2 (0.63) | ALKBH2HPGDSALKBH1EGLN1 | |
| SCHEMBL30770251 | 0.76 | CREBBP (0.67) | ALKBH1EGLN1 | |
| SCHEMBL20532416 | 0.76 | CREBBP (0.67) | ALKBH1EGLN1 | |
| SCHEMBL23381882 | 0.75 | CREBBP (0.41) | — | |
| SCHEMBL21877551 | 0.75 | BRD4 (0.42) | ALKBH1 | |
| SCHEMBL21484069 | 0.75 | CREBBP (0.41) | — | |
| SCHEMBL20738212 | 0.75 | KDM4E (0.46) | — | |
| SCHEMBL27748840 | 0.75 | TDO2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795249-B2 | Certain pyrazoline derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795249-B2 | Certain pyrazoline derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080171754-A1 | Certain pyrazoline derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| US-20080171754-A1 | Certain pyrazoline derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008079277-A1 | CERTAIN PYRAZOLINE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171754-A1 | Certain pyrazoline derivatives with kinase inhibitory activity | MAP3K5, MAP4K5, MAP3K20 | ALKBH2 4501/4885HPGDS 1072/4885ALKBH1 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.